Engineered Fibroblast Therapy for Osteoclast-Osteoblast Imbalance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Osteoporosis is caused by an imbalance in the coupling interactive process between osteoclast and osteoblast functions, leading to excessive bone resorption and insufficient bone formation, which is not effectively addressed by existing treatments.

Innovation Solution

Administering fibroblasts that have been transfected or dedifferentiated to enhance homing to bone niches, inhibit RANK ligand production, and stimulate osteoblast activity, thereby reducing osteoclast activation and enhancing bone formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used for osteoporosis, then treatment is provided, but the imbalance between osteoclast and osteoblast functions is not effectively addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address cellular imbalance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses fibroblasts as intermediary cells that mediate the interaction between osteoclasts and osteoblasts. These fibroblasts are engineered to express specific factors that regulate bone remodeling, serving as a bridge to restore the coupling balance between bone resorption and formation processes.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the functional parameters of fibroblasts through genetic engineering, transforming them into cells that can actively regulate osteoclast and osteoblast functions. This involves modifying gene expression levels and cellular behavior to achieve therapeutic effects on bone density and remodeling balance.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If fibroblasts are administered to inhibit osteoclast activity, then bone resorption is reduced, but the complexity of cell preparation and administration increases

Engineering Contradiction:

Improvebone resorption inhibitionVSAvoidcell therapy preparation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The fibroblasts are pre-engineered with the necessary genetic modifications and functional characteristics before administration. This preliminary preparation ensures that the cells are ready to perform their therapeutic function immediately upon implantation, reducing the need for complex post-administration interventions.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The engineered fibroblasts are designed to autonomously perform their therapeutic function of regulating bone remodeling without requiring continuous external intervention. Once administered, these cells self-regulate osteoclast and osteoblast activity through their engineered mechanisms, reducing the need for repeated administrations or complex monitoring systems.

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS12544407B2Fibroblast cell therapy for treatment of osteoporosis

Publication Date: 2026.02.10 FIBROBIOLOGICS INC

AI summary

Embodiments of the disclosure include methods and compositions related to modulation of bone using particular fibroblasts. The modulation includes reducing osteoclast activity and/or activation and/or stimulating osteoblast activity. In particular cases, bone is modulated in an individual with a bone condition, such as osteoporosis. Particular fibroblasts may be delivered to reduce inflammatory cytokine production including RANK ligand.